Analyst Expectations For Biomarin Pharmaceutical's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) over the past three months, with a recent trend towards lowering price targets. The average 12-month price target has decreased by 5.06% to $102.33. Despite this, BioMarin shows strong financial performance with a 19.61% revenue growth rate and a net margin of 15.05%.
October 04, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioMarin Pharmaceutical has received mixed analyst ratings, with a recent trend of lowered price targets. The average 12-month price target has decreased by 5.06% to $102.33. Despite this, the company shows strong financial performance with a 19.61% revenue growth rate and a net margin of 15.05%.
The mixed analyst ratings and lowered price targets suggest uncertainty in the short-term stock performance. However, BioMarin's strong financial metrics, such as revenue growth and net margin, provide a positive outlook, balancing the negative sentiment from analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100